Dr. Klempner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
MGH Cancer Center
55 Fruit Street
Boston, MA 02114
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
- Brigham and Women's HospitalResidency, Internal Medicine, 2007 - 2010
- University of Massachusetts Medical SchoolClass of 2007
- Hamilton CollegeB.A., Magna Cum Laude, 2003
Certifications & Licensure
- ME State Medical License 2021 - 2026
- MA State Medical License 2010 - 2025
- CA State Medical License 2013 - 2020
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Standing Ovation Award Cedars-Sinai Medical Center, 2016
- SuperDoctors Southern CA Rising Star 2016-2017
- Top Physician Communicator UC Irvine, 2015
- Join now to see all
Publications & Presentations
PubMed
- Development of a fibrin-targeted theranostic for gastric cancer.Shadi A Esfahani, Li Ma, Shriya Krishna, Hua Ma, Shvan J Raheem
Science Translational Medicine. 2024-12-11 - 2 citationsSpatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases.Joseph J Zhao, Chin-Ann Johnny Ong, Supriya Srivastava, Daryl Kai Ann Chia, Haoran Ma
Gastroenterology. 2024-12-01 - Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.Eric Michael Lander, Vasily N Aushev, Brandon M Huffman, Diana Hanna, Punashi Dutta
JCO Precision Oncology. 2024-12-01
Journal Articles
- PD-1 as an emerging target in gastric cancer: current evidenceTran PN, Sarkissian S, Chao J, Klempner SJ, Gastrointestinal Cancer: Targets and Therapy, 1/1/2017
- Moving Molecular Subtypes to the Clinic in Gastric CancerChao J, Lee J, Klempner SJ, Transl Cancer Res, 1/1/2016
- ROS1 (c-ros oncogene 1)Klempner SJ, Ou, SH, Atlas Genet Cytogenet Oncol Haematol, 1/1/2014
Books/Book Chapters
Abstracts/Posters
- Neoadjuvant Chemotherapy Improves Survival In Patients With Clinical T4b Colon Cancer.Dehal A, Graff-Baker AN, Voung B, Fischer T, Klempner SJ, et al, Digestive Disease Week, Chicago, IL, 1/6/2017
- Genomic profiling of circulating tumor DNA (ctDNA) from patients with advanced cancers of the GI tract and anus.Schrock AB, Young L, Klempner SJ, Bordoni R, Ross JS, et al, GI ASCO, 1/1/2017
- Comprehensive genomic profiling (CGP) of esophageal and tubular GI tumors identifies differing frequencies of ErbB family member amplifications with therapeutic implic...Bailey M, Ali SM, Schrock AB, Klempner SJ, George B, Lipson D, et al, GI ASCO, 1/1/2017
- Join now to see all
Lectures
- Early Is Better: The Roles of Prevention, Screening, and Early DetectionASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Help From Within: DNA to Personalized Therapy for Gastric Cancer1/18/2017
- Join now to see all
Authored Content
- Immunotherapies as a Targeted Therapy to Accelerate Personalized CareFebruary 2020
- Immunotherapies as a Targeted Therapy to Accelerate Personalized CareFebruary 2020
Press Mentions
- FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction CancerOctober 23rd, 2024
- Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal CancerOctober 21st, 2024
- Novel Targeted Drug Approved for Stomach CancersOctober 18th, 2024
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- ESMOMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: